drugset / Trial / NCT06212583
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
Phase 2
Active not recruiting
88 enrolled
University of Maryland, Baltimore
Janssen Scientific Affairs, LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of care and addition of 6-months of niraparib/abiraterone acetate combination pills and prednisone for participants with recurrent metastatic prostate cancer.
Timeline
- Start
- 2024-04-17
- Primary completion
- 2028-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abiraterone acetate | Small molecule | — | — |
| Comparator | Niraparib | Small molecule | — | — |